Development gaps and needs
Science
The decarbonization case for this pathway cannot be built without a reliable supply of low-cost biomass and better understanding of the impacts on livestock performance, which requires resolving the production consistency, and impact testing gaps addressed in this subsection.
Seaweed biomass supply
There is not enough seaweed in production to support animal feed research and commercial development.
The animal feed sector requires reliable, high-volume biomass supply to conduct meaningful trials, attract investment, and bring products to scale. Current global production is dominated by a small number of species grown for food and hydrocolloid markets; dedicated feed-grade supply chains barely exist in most producing regions. Without a stable biomass base, downstream product development stalls regardless of market demand (World Bank, 2023). See the chapter “Cultivation and Drying Considerations” for more information.
Genomic and phenotypic diversity
Lack of intentional species selection constrains consistent production of high-quality products
Seaweed’s nutritional and bioactive composition varies considerably across species, geographies, seasonality, and maturity. Most commercial feed products are made from whatever biomass is available rather than strains chosen for end-use performance. This produces variable product quality and makes it difficult to demonstrate consistent efficacy to buyers (e.g., Halfdanarson et al., 2019; Emblemsvåg et al., 2020). Investment in genotype-phenotype mapping and systematic species/strain and site selection criteria would enable more reliable production and improve cost-competitiveness with established alternatives (González-Mesa et al., 2023).
Characterizing and mapping seaweed chemical composition
The specific compounds in seaweed responsible for improving livestock health and productivity have not been identified with sufficient precision to support product development or regulatory approval Seaweed-based feed products improve animal health, growth rates, and immune function across multiple studies, but the active compounds driving those effects are largely unknown. Without knowing which compounds matter — and in what concentrations — product developers cannot target them through cultivation or processing, and regulators cannot set meaningful approval criteria. ‘Omics approaches (e.g., genomics, transcriptomics, metabolomics) using strains with and without candidate genes that produce the chemical compound of interest can validate chemical characterization (World Bank Report, 2023).
Impacts on livestock performance
There is not enough long-term evidence on the effects of seaweed-based feed on livestock health, productivity, and product quality to satisfy buyer or regulatory requirements.
Most existing trials are short-term, conducted at laboratory or pilot scale, and focused on a small number of livestock species. The lack of long-term data reduces buyer confidence and prevents regulators from setting safety limits or validating health claims (González-Mesa et al., 2023). Long-term commercial trials are needed to address this barrier.
The optimal inclusion rate for seaweed in feed has not been established systematically across livestock types, species, and seasons
Short-term performance data indicates that the right inclusion level varies by livestock species, seaweed species, active compound concentration, and season. In some cases, too much inclusion of seaweed causes weight loss, reduced palatability, or mineral overload in some species. Dose-response studies across the main livestock categories (ruminants, swine, poultry, aquaculture) would produce the inclusion-rate guidance that product developers and feed formulators currently lack (Costa et al., 2021).
Public health
The extent to which seaweed contaminants — iodine, heavy metals, marine biotoxins — accumulate in livestock products for human consumption is not established
Seaweed can contain high concentrations of iodine, heavy metals (e.g., lead, arsenic, mercury, cadmium), and marine biotoxins, yet there is limited data on the magnitude to which these compounds accumulate in livestock fed with seaweed and subsequently products for human consumption (FAO, 2024). Clinical health trials need to be done to confirm that products are safe for indirect human consumption.
Seaweed biomass supply
There is not enough seaweed in production to support animal feed research and commercial development. The animal feed sector requires reliable, high-volume biomass supply to conduct meaningful trials, attract investment, and bring products to scale. Current global production is dominated by a small number of species grown for food and hydrocolloid markets; dedicated feed-grade supply chains barely exist in most producing regions. Without a stable biomass base, downstream product development stalls regardless of market demand (World Bank, 2023). See the chapter "Cultivation and Drying Considerations" for more information.Genomic and phenotypic diversity
Lack of intentional species selection constrains consistent production of high-quality products Seaweed's nutritional and bioactive composition varies considerably across species, geographies, seasonality, and maturity. Most commercial feed products are made from whatever biomass is available rather than strains chosen for end-use performance. This produces variable product quality and makes it difficult to demonstrate consistent efficacy to buyers (e.g., Halfdanarson et al., 2019; Emblemsvåg et al., 2020). Investment in genotype-phenotype mapping and systematic species/strain and site selection criteria would enable more reliable production and improve cost-competitiveness with established alternatives (González-Mesa et al., 2023).Characterizing and mapping seaweed chemical composition
The specific compounds in seaweed responsible for improving livestock health and productivity have not been identified with sufficient precision to support product development or regulatory approval Seaweed-based feed products improve animal health, growth rates, and immune function across multiple studies, but the active compounds driving those effects are largely unknown. Without knowing which compounds matter — and in what concentrations — product developers cannot target them through cultivation or processing, and regulators cannot set meaningful approval criteria. ‘Omics approaches (e.g., genomics, transcriptomics, metabolomics) using strains with and without candidate genes that produce the chemical compound of interest can validate chemical characterization (World Bank Report, 2023).Impacts on livestock performance
There is not enough long-term evidence on the effects of seaweed-based feed on livestock health, productivity, and product quality to satisfy buyer or regulatory requirements. Most existing trials are short-term, conducted at laboratory or pilot scale, and focused on a small number of livestock species. The lack of long-term data reduces buyer confidence and prevents regulators from setting safety limits or validating health claims (González-Mesa et al., 2023). Long-term commercial trials are needed to address this barrier. The optimal inclusion rate for seaweed in feed has not been established systematically across livestock types, species, and seasons Short-term performance data indicates that the right inclusion level varies by livestock species, seaweed species, active compound concentration, and season. In some cases, too much inclusion of seaweed causes weight loss, reduced palatability, or mineral overload in some species. Dose-response studies across the main livestock categories (ruminants, swine, poultry, aquaculture) would produce the inclusion-rate guidance that product developers and feed formulators currently lack (Costa et al., 2021).Public health
The extent to which seaweed contaminants — iodine, heavy metals, marine biotoxins — accumulate in livestock products for human consumption is not established Seaweed can contain high concentrations of iodine, heavy metals (e.g., lead, arsenic, mercury, cadmium), and marine biotoxins, yet there is limited data on the magnitude to which these compounds accumulate in livestock fed with seaweed and subsequently products for human consumption (FAO, 2024). Clinical health trials need to be done to confirm that products are safe for indirect human consumption.Seaweed biomass supply
There is not enough seaweed in production to support animal feed research and commercial development. The animal feed sector requires reliable, high-volume biomass supply to conduct meaningful trials, attract investment, and bring products to scale. Current global production is dominated by a small number of species grown for food and hydrocolloid markets; dedicated feed-grade supply chains barely exist in most producing regions. Without a stable biomass base, downstream product development stalls regardless of market demand (World Bank, 2023). See the chapter "Cultivation and Drying Considerations" for more information.Genomic and phenotypic diversity
Lack of intentional species selection constrains consistent production of high-quality products Seaweed's nutritional and bioactive composition varies considerably across species, geographies, seasonality, and maturity. Most commercial feed products are made from whatever biomass is available rather than strains chosen for end-use performance. This produces variable product quality and makes it difficult to demonstrate consistent efficacy to buyers (e.g., Halfdanarson et al., 2019; Emblemsvåg et al., 2020). Investment in genotype-phenotype mapping and systematic species/strain and site selection criteria would enable more reliable production and improve cost-competitiveness with established alternatives (González-Mesa et al., 2023).Characterizing and mapping seaweed chemical composition
The specific compounds in seaweed responsible for improving livestock health and productivity have not been identified with sufficient precision to support product development or regulatory approval Seaweed-based feed products improve animal health, growth rates, and immune function across multiple studies, but the active compounds driving those effects are largely unknown. Without knowing which compounds matter — and in what concentrations — product developers cannot target them through cultivation or processing, and regulators cannot set meaningful approval criteria. ‘Omics approaches (e.g., genomics, transcriptomics, metabolomics) using strains with and without candidate genes that produce the chemical compound of interest can validate chemical characterization (World Bank Report, 2023).Impacts on livestock performance
There is not enough long-term evidence on the effects of seaweed-based feed on livestock health, productivity, and product quality to satisfy buyer or regulatory requirements. Most existing trials are short-term, conducted at laboratory or pilot scale, and focused on a small number of livestock species. The lack of long-term data reduces buyer confidence and prevents regulators from setting safety limits or validating health claims (González-Mesa et al., 2023). Long-term commercial trials are needed to address this barrier. The optimal inclusion rate for seaweed in feed has not been established systematically across livestock types, species, and seasons Short-term performance data indicates that the right inclusion level varies by livestock species, seaweed species, active compound concentration, and season. In some cases, too much inclusion of seaweed causes weight loss, reduced palatability, or mineral overload in some species. Dose-response studies across the main livestock categories (ruminants, swine, poultry, aquaculture) would produce the inclusion-rate guidance that product developers and feed formulators currently lack (Costa et al., 2021).Public health
The extent to which seaweed contaminants — iodine, heavy metals, marine biotoxins — accumulate in livestock products for human consumption is not established Seaweed can contain high concentrations of iodine, heavy metals (e.g., lead, arsenic, mercury, cadmium), and marine biotoxins, yet there is limited data on the magnitude to which these compounds accumulate in livestock fed with seaweed and subsequently products for human consumption (FAO, 2024). Clinical health trials need to be done to confirm that products are safe for indirect human consumption.Seaweed biomass supply
There is not enough seaweed in production to support animal feed research and commercial development. The animal feed sector requires reliable, high-volume biomass supply to conduct meaningful trials, attract investment, and bring products to scale. Current global production is dominated by a small number of species grown for food and hydrocolloid markets; dedicated feed-grade supply chains barely exist in most producing regions. Without a stable biomass base, downstream product development stalls regardless of market demand (World Bank, 2023). See the chapter "Cultivation and Drying Considerations" for more information.Genomic and phenotypic diversity
Lack of intentional species selection constrains consistent production of high-quality products Seaweed's nutritional and bioactive composition varies considerably across species, geographies, seasonality, and maturity. Most commercial feed products are made from whatever biomass is available rather than strains chosen for end-use performance. This produces variable product quality and makes it difficult to demonstrate consistent efficacy to buyers (e.g., Halfdanarson et al., 2019; Emblemsvåg et al., 2020). Investment in genotype-phenotype mapping and systematic species/strain and site selection criteria would enable more reliable production and improve cost-competitiveness with established alternatives (González-Mesa et al., 2023).Characterizing and mapping seaweed chemical composition
The specific compounds in seaweed responsible for improving livestock health and productivity have not been identified with sufficient precision to support product development or regulatory approval Seaweed-based feed products improve animal health, growth rates, and immune function across multiple studies, but the active compounds driving those effects are largely unknown. Without knowing which compounds matter — and in what concentrations — product developers cannot target them through cultivation or processing, and regulators cannot set meaningful approval criteria. ‘Omics approaches (e.g., genomics, transcriptomics, metabolomics) using strains with and without candidate genes that produce the chemical compound of interest can validate chemical characterization (World Bank Report, 2023).Impacts on livestock performance
There is not enough long-term evidence on the effects of seaweed-based feed on livestock health, productivity, and product quality to satisfy buyer or regulatory requirements. Most existing trials are short-term, conducted at laboratory or pilot scale, and focused on a small number of livestock species. The lack of long-term data reduces buyer confidence and prevents regulators from setting safety limits or validating health claims (González-Mesa et al., 2023). Long-term commercial trials are needed to address this barrier. The optimal inclusion rate for seaweed in feed has not been established systematically across livestock types, species, and seasons Short-term performance data indicates that the right inclusion level varies by livestock species, seaweed species, active compound concentration, and season. In some cases, too much inclusion of seaweed causes weight loss, reduced palatability, or mineral overload in some species. Dose-response studies across the main livestock categories (ruminants, swine, poultry, aquaculture) would produce the inclusion-rate guidance that product developers and feed formulators currently lack (Costa et al., 2021).Public health
The extent to which seaweed contaminants — iodine, heavy metals, marine biotoxins — accumulate in livestock products for human consumption is not established Seaweed can contain high concentrations of iodine, heavy metals (e.g., lead, arsenic, mercury, cadmium), and marine biotoxins, yet there is limited data on the magnitude to which these compounds accumulate in livestock fed with seaweed and subsequently products for human consumption (FAO, 2024). Clinical health trials need to be done to confirm that products are safe for indirect human consumption.Seaweed biomass supply
There is not enough seaweed in production to support animal feed research and commercial development. The animal feed sector requires reliable, high-volume biomass supply to conduct meaningful trials, attract investment, and bring products to scale. Current global production is dominated by a small number of species grown for food and hydrocolloid markets; dedicated feed-grade supply chains barely exist in most producing regions. Without a stable biomass base, downstream product development stalls regardless of market demand (World Bank, 2023). See the chapter "Cultivation and Drying Considerations" for more information.Genomic and phenotypic diversity
Lack of intentional species selection constrains consistent production of high-quality products Seaweed's nutritional and bioactive composition varies considerably across species, geographies, seasonality, and maturity. Most commercial feed products are made from whatever biomass is available rather than strains chosen for end-use performance. This produces variable product quality and makes it difficult to demonstrate consistent efficacy to buyers (e.g., Halfdanarson et al., 2019; Emblemsvåg et al., 2020). Investment in genotype-phenotype mapping and systematic species/strain and site selection criteria would enable more reliable production and improve cost-competitiveness with established alternatives (González-Mesa et al., 2023).Characterizing and mapping seaweed chemical composition
The specific compounds in seaweed responsible for improving livestock health and productivity have not been identified with sufficient precision to support product development or regulatory approval Seaweed-based feed products improve animal health, growth rates, and immune function across multiple studies, but the active compounds driving those effects are largely unknown. Without knowing which compounds matter — and in what concentrations — product developers cannot target them through cultivation or processing, and regulators cannot set meaningful approval criteria. ‘Omics approaches (e.g., genomics, transcriptomics, metabolomics) using strains with and without candidate genes that produce the chemical compound of interest can validate chemical characterization (World Bank Report, 2023).Impacts on livestock performance
There is not enough long-term evidence on the effects of seaweed-based feed on livestock health, productivity, and product quality to satisfy buyer or regulatory requirements. Most existing trials are short-term, conducted at laboratory or pilot scale, and focused on a small number of livestock species. The lack of long-term data reduces buyer confidence and prevents regulators from setting safety limits or validating health claims (González-Mesa et al., 2023). Long-term commercial trials are needed to address this barrier. The optimal inclusion rate for seaweed in feed has not been established systematically across livestock types, species, and seasons Short-term performance data indicates that the right inclusion level varies by livestock species, seaweed species, active compound concentration, and season. In some cases, too much inclusion of seaweed causes weight loss, reduced palatability, or mineral overload in some species. Dose-response studies across the main livestock categories (ruminants, swine, poultry, aquaculture) would produce the inclusion-rate guidance that product developers and feed formulators currently lack (Costa et al., 2021).Public health
The extent to which seaweed contaminants — iodine, heavy metals, marine biotoxins — accumulate in livestock products for human consumption is not established Seaweed can contain high concentrations of iodine, heavy metals (e.g., lead, arsenic, mercury, cadmium), and marine biotoxins, yet there is limited data on the magnitude to which these compounds accumulate in livestock fed with seaweed and subsequently products for human consumption (FAO, 2024). Clinical health trials need to be done to confirm that products are safe for indirect human consumption.Seaweed biomass supply
There is not enough seaweed in production to support animal feed research and commercial development. The animal feed sector requires reliable, high-volume biomass supply to conduct meaningful trials, attract investment, and bring products to scale. Current global production is dominated by a small number of species grown for food and hydrocolloid markets; dedicated feed-grade supply chains barely exist in most producing regions. Without a stable biomass base, downstream product development stalls regardless of market demand (World Bank, 2023).Genomic and phenotypic diversity
Lack of intentional species selection constrains consistent production of high-quality products Seaweed's nutritional and bioactive composition varies considerably across species, geographies, seasonality, and maturity. Most commercial feed products are made from whatever biomass is available rather than strains chosen for end-use performance. This produces variable product quality and makes it difficult to demonstrate consistent efficacy to buyers (e.g., Halfdanarson et al., 2019; Emblemsvåg et al., 2020). Investment in genotype-phenotype mapping and systematic species/strain and site selection criteria would enable more reliable production and improve cost-competitiveness with established alternatives (González-Mesa et al., 2023).Characterizing and mapping seaweed chemical composition
The specific compounds in seaweed responsible for improving livestock health and productivity have not been identified with sufficient precision to support product development or regulatory approval Seaweed-based feed products improve animal health, growth rates, and immune function across multiple studies, but the active compounds driving those effects are largely unknown. Without knowing which compounds matter — and in what concentrations — product developers cannot target them through cultivation or processing, and regulators cannot set meaningful approval criteria. ‘Omics approaches (e.g., genomics, transcriptomics, metabolomics) using strains with and without candidate genes that produce the chemical compound of interest can validate chemical characterization (World Bank Report, 2023).Impacts on livestock performance
There is not enough long-term evidence on the effects of seaweed-based feed on livestock health, productivity, and product quality to satisfy buyer or regulatory requirements. Most existing trials are short-term, conducted at laboratory or pilot scale, and focused on a small number of livestock species. The lack of long-term data reduces buyer confidence and prevents regulators from setting safety limits or validating health claims (González-Mesa et al., 2023). Long-term commercial trials are needed to address this barrier. The optimal inclusion rate for seaweed in feed has not been established systematically across livestock types, species, and seasons Short-term performance data indicates that the right inclusion level varies by livestock species, seaweed species, active compound concentration, and season. In some cases, too much inclusion of seaweed causes weight loss, reduced palatability, or mineral overload in some species. Dose-response studies across the main livestock categories (ruminants, swine, poultry, aquaculture) would produce the inclusion-rate guidance that product developers and feed formulators currently lack (Costa et al., 2021).Public health
The extent to which seaweed contaminants — iodine, heavy metals, marine biotoxins — accumulate in livestock products for human consumption is not established Seaweed can contain high concentrations of iodine, heavy metals (e.g., lead, arsenic, mercury, cadmium), and marine biotoxins, yet there is limited data on the magnitude to which these compounds accumulate in livestock fed with seaweed and subsequently products for human consumption (FAO, 2024). Clinical health trials need to be done to confirm that products are safe for indirect human consumption.Seaweed biomass supply
There is not enough seaweed in production to support animal feed research and commercial development. The animal feed sector requires reliable, high-volume biomass supply to conduct meaningful trials, attract investment, and bring products to scale. Current global production is dominated by a small number of species grown for food and hydrocolloid markets; dedicated feed-grade supply chains barely exist in most producing regions. Without a stable biomass base, downstream product development stalls regardless of market demand (World Bank, 2023).Genomic and phenotypic diversity
Lack of intentional species selection constrains consistent production of high-quality products Seaweed's nutritional and bioactive composition varies considerably across species, geographies, seasonality, and maturity. Most commercial feed products are made from whatever biomass is available rather than strains chosen for end-use performance. This produces variable product quality and makes it difficult to demonstrate consistent efficacy to buyers (e.g., Halfdanarson et al., 2019; Emblemsvåg et al., 2020). Investment in genotype-phenotype mapping and systematic species/strain and site selection criteria would enable more reliable production and improve cost-competitiveness with established alternatives (González-Mesa et al., 2023).Characterizing and mapping seaweed chemical composition
The specific compounds in seaweed responsible for improving livestock health and productivity have not been identified with sufficient precision to support product development or regulatory approval Seaweed-based feed products improve animal health, growth rates, and immune function across multiple studies, but the active compounds driving those effects are largely unknown. Without knowing which compounds matter — and in what concentrations — product developers cannot target them through cultivation or processing, and regulators cannot set meaningful approval criteria. ‘Omics approaches (e.g., genomics, transcriptomics, metabolomics) using strains with and without candidate genes that produce the chemical compound of interest can validate chemical characterization (World Bank Report, 2023).Impacts on livestock performance
There is not enough long-term evidence on the effects of seaweed-based feed on livestock health, productivity, and product quality to satisfy buyer or regulatory requirements. Most existing trials are short-term, conducted at laboratory or pilot scale, and focused on a small number of livestock species. The lack of long-term data reduces buyer confidence and prevents regulators from setting safety limits or validating health claims (González-Mesa et al., 2023). Long-term commercial trials are needed to address this barrier. The optimal inclusion rate for seaweed in feed has not been established systematically across livestock types, species, and seasons. Short-term performance data indicates that the right inclusion level varies by livestock species, seaweed species, active compound concentration, and season. In some cases, too much inclusion of seaweed causes weight loss, reduced palatability, or mineral overload in some species. Dose-response studies across the main livestock categories (ruminants, swine, poultry, aquaculture) would produce the inclusion-rate guidance that product developers and feed formulators currently lack (Costa et al., 2021).Public health
The extent to which seaweed contaminants — iodine, heavy metals, marine biotoxins — accumulate in livestock products for human consumption is not established. Seaweed can contain high concentrations of iodine, heavy metals (e.g., lead, arsenic, mercury, cadmium), and marine biotoxins, yet there is limited data on the magnitude to which these compounds accumulate in livestock fed with seaweed and subsequently products for human consumption (FAO, 2024). Clinical health trials need to be done to confirm that products are safe for indirect human consumption.Processing and Engineering
The gaps in this subsection determine the processing carbon intensity of seaweed feed products: post-harvest drying is the single largest contributor to the product lifecycle footprint, and until lower-carbon alternatives are commercially viable, the net climate benefit per ton of feed applied is materially reduced
Post-harvest drying is the largest single contributor to the carbon footprint of seaweed-based feed products and raises costs substantially
Drying seaweed for animal feed makes up a substantial portion of products’ carbon footprints. Co-locating renewable or waste energy with processing operations, and developing lower-energy drying alternatives, are priority technical targets. See the “Cultivation and Drying Considerations” chapter for more information.
Extraction methods are not optimized for yield, energy use or product stability
Conventional extraction relies on heat, solvents, acid, and time, which degrades heat-sensitive bioactive compounds and adds energy cost. Novel approaches — enzyme-assisted, ultrasound-assisted, and subcritical water extraction — can improve yields and reduce solvent use, but remain at laboratory scale (TRL 1–3) for most seaweed feed applications. Comparative efficacy studies are needed to test and develop these extraction technologies that can produce high-quality and stable products with lower environmental impact, as well as development of seaweed-specific extraction ingredients (e.g., EAE; Garcia-Vaquero et al., 2017; Ahmed et al., 2023).
Markets and Investments
The gaps in this subsection reflect on the challenge of determining whether the full lifecycle climate benefit of seaweed-based feed can be quantified, including land-use displacement of terrestrial feed crops, and sequestration during cultivation.
Existing lifecycle assessments do not capture the full climate impact of seaweed-based feed products as well as incumbent products, which limits investor confidence and the policy case for the sector
Existing assessments omit carbon sequestration during cultivation, emissions at product end-of-life, comparative land-use impacts against terrestrial incumbents, and chemical product avoidance, leaving the realistic mitigation case unresolved. Expanding LCA programs to cover full product lifecycles with standardized methodologies would strengthen both the investment and policy case (Halfdanarson et al., 2019; Chaurasiya et al., 2026).
Policy and Governance
The gaps in this subsection reflect that seaweed-based feed products can be sold across major markets without harmonized contaminant limits and mandatory composition disclosure. Cross-border trade will remain restricted and the addressable market for climate-relevant volumes of feed products is constrained.
Regulatory frameworks for seaweed in animal feed are fragmented across jurisdictions, inconsistently applied, and lack a common international standard
National contaminant thresholds for arsenic, cadmium, iodine, and mercury differ substantially across the EU, US, Canada, China, and Australia and were not set specifically for seaweed. No Codex standard for seaweed in animal feed exists, meaning there is no internationally recognized benchmark that producers can target or that regulators can reference when setting national rules (FAO, 2022; Cottier-Cook et al., 2023).
Absent transparency requirements on composition and contaminant limits create market opacity and impede buyer trust
In most markets, producers have no obligation to disclose active compound concentrations, contaminant levels, species identity, or harvest source — so buyers and regulators cannot compare products or verify safety claims (Morais et al., 2020). Canada’s mandatory iodine labeling requirements is one of the few rules that cover all livestock feed materials. International production guidelines with mandatory composition reporting, modeled on existing food safety frameworks, would establish the transparency the market requires.
How to submit comments:
Thanks for helping to advance these roadmaps. Here is how it works!
Or, send general feedback to info@oceanvisions.org
All submitted comments will be reviewed by the Ocean Visions team to ensure that they are true, verifiable, and additive before being added to the road maps. You can increase the likelihood that your comments will be incorporated into the road maps by providing references (where appropriate).